# Univercells

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/univercells

- Industry: Biotechnology
- Headquarters: Charleroi, Belgium
- Website: www.univercells.com
- Total disclosed funding: $86M
- Latest round: Series D (Oct 13, 2022)
- Investors on record: 16

## About

Based in Belgium, and founded in 2013, Universals SA operates as a life sciences company that offers end-to-end biotech solutions to produce vaccines and biotherapeutics. The company was founded by its CEO, Hugues Bultot, and CTO, José Castillo. In October 2022, Univercells SA raised EUR 44 million in Series D funding co-led by 3d investors, Global Health Investment Corporation, Adjuvant Capital, and AdBio Partners.

Universals provides products and services through its divisions: Univercells Technologies, a biomanufacturing firm that offers scale-X bioreactors; Exothera, a CDMO (contract development and manufacturing organization) that focuses on viral vectors targeting cell and gene therapy and vaccine development; Quantoom Biosciences, a biotech firm that offers Nfinity, an mRNA production platform; Unizima, a biomanufacturing company that provides biologics such as vaccines, monoclonal antibodies, and insulin; and RLM Consulting, a consulting firm that offers regulatory compliance for small and medium-sized biotech and pharmaceutical companies.

The company plans to use the funds raised in October 2022 to support the development of Quantoom Biosciences' RNA platform.

## Funding rounds

- Series D, Oct 13, 2022, $43M — In-Q-Tel, SFPI-FPIM, 3D Investments, SRIW, AdBio Partners, Adjuvant Capital, TCD Capital, Global Health Investment Advisors
- Series C, Sep 4, 2020, $30M — Soros Economic Development Fund, Korea Investment Partners, SFPI-FPIM, Sambrinvest, Farallon Capital Management, SRIW, Inventures, Adjuvant Capital, TCD Capital
- Series B, Jun 28, 2018, $9.3M — Korea Investment Partners, Inventures, Global Health Impact Funds, TCD Capital, Innovation Fund
- Series A, Sep 15, 2017, $3.7M — Takeda Ventures

## Investors

- Takeda Ventures (https://capitalatlas.ai/funds/takeda-ventures) — Series A
- Korea Investment Partners (https://capitalatlas.ai/funds/korea-investment-partners) — Series B, Series C
- Inventures (https://capitalatlas.ai/funds/inventures) — Series B, Series C
- Global Health Impact Funds (https://capitalatlas.ai/funds/global-health-impact-funds) — Series B
- TCD Capital (https://capitalatlas.ai/funds/tcd-capital) — Series B, Series C, Series D
- Innovation Fund (https://capitalatlas.ai/funds/innovation-fund) — Series B
- Soros Economic Development Fund — Series C
- SFPI-FPIM — Series C, Series D
- Sambrinvest (https://capitalatlas.ai/funds/sambrinvest) — Series C
- Farallon Capital Management (https://capitalatlas.ai/funds/farallon-capital-management) — Series C
- SRIW — Series C, Series D
- Adjuvant Capital (https://capitalatlas.ai/funds/adjuvant-capital) — Series C, Series D
- In-Q-Tel (https://capitalatlas.ai/funds/in-q-tel) — Series D
- 3D Investments (https://capitalatlas.ai/funds/3d-investments) — Series D
- AdBio Partners (https://capitalatlas.ai/funds/adbio-partners) — Series D
- Global Health Investment Advisors — Series D